While many ribosome-targeting toxins are harmful, not all interactions result in toxicity. In some therapeutic contexts, ribosome-inactivating agents are used to selectively kill cancer cells or inhibit viral replication. For instance, certain derivatives of RIPs are being explored as anti-cancer agents, exploiting their ability to selectively target and kill rapidly dividing cells.
